DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

Information source: Universita di Verona
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: aripiprazole (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Universita di Verona

Official(s) and/or principal investigator(s):
Michele Tansella, MD, Study Chair, Affiliation: Universita di Verona

Summary

The principal clinical question to be answered by CHAT (Clozapine Haloperidol Aripiprazole Trial) is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared to combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time.

Clinical Details

Official title: Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Withdrawal from allocated treatment within 3 months.

Secondary outcome:

Withdrawal from allocated treatment within 12 months of follow-up.

Time to withdrawal from allocated treatment.

Severity of illness, measured at month 3 and 12.

Withdrawal from study treatment, due to adverse reactions, within 3 and 12 months.

Concurrent use of adjunctive medication within 3 and 12 months.

Concurrent use of antiparkinson medication within 3 and 12 months.

Adverse events within 3 and 12 months.

Biological parameters, measured at month 3 and 12.

Metabolic syndrome within 3 and 12 months.

Subjective tolerability of antipsychotic drugs, measured at month 3 and 12.

Deliberate self-harm within 3 and 12 months.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by DSM-IV criteria). 2. Treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects. 3. Unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis) 4. Age 18 and above. 5. Agreement between investigator and patient to enter the study. 6. The patient is normally resident in Italy. 7. It is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol. 8. Uncertainty about which trial treatment would be best for the participant. 9. No medical disorder or condition contraindicates either of the investigational drugs. 10. Agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).

Locations and Contacts

University of Verona, Verona 37124, Italy
Additional Information

Click here for more information about the CHAT study

Starting date: September 2006
Last updated: February 17, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017